On the basis of the demonstration of substantial efficacy in the above phase I study, crizotinib has recently been approved by the United States Food and Drug Administration (FDA) as a treatment for patients with ROS1 fusion-positive NSCLC. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.